Quantum Leap Healthcare Collaborative
search
News

I-SPY in the News

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
Close
Close
Close
Close
I-SPY Email List Sign-up

Thank you, your subscription is activated.

If you change your mind, you can unsubscribe at any time.
Oops! Something went wrong while submitting the form.
Close
Close

Highlights

Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting

Natera, Inc.

April 11, 2022

Dr. Laura Esserman among recipients of 2020 Brinker Awards for Scientific Distinction

October 1, 2020

Genomic Testing in Breast Cancer May Enhance Personalized Treatment: Update of I-SPY 2

ASCO Post

November 28, 2018

Recent Coverage

November 29, 2017
-
Targeted Oncology
New Treatment Options Emerging for Patients With HER2+ Breast Cancer
February 23, 2017
-
R&D Magazine
Three Skills Developers Will Need to Thrive in the New Era of Genomic Medicine
January 5, 2017
-
Huffington Post
Top Ten Medical Research Issues and Trends to Watch in 2017
October 26, 2016
-
Cancer Therapy Advisor
Adaptive randomization and the I-SPY 2 trial platform
October 26, 2016
-
Clin Adv Hem Onc
The I-SPY approach to drug development: An interview with Laura Esserman
September 5, 2016
-
BioCentury
Back to School: Haste, not waste
July 7, 2016
-
NEJM
I-SPY 2 - A glimpse of future phase 2 drug development?
June 25, 2016
-
Oncology Times
I-SPY 2 shows efficacy of T-DM1-Pertuzumab
November 2, 2015
-
Managed Care Mag.
Can Platform Trials Speed Cancer Drug Development?
September 28, 2015
-
NY Times
A breast cancer surgeon who keeps challenging the status quo
December 13, 2013
-
Wall St Journal
Two Experimental Breast-Cancer Drugs Pass Major Milestone in Study
October 2, 2010
-
Wall St Journal
A new Rx for medicine

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative